June 18 (Reuters) - The U.S. Food and Drug
Administration on Wednesday approved Gilead Sciences' ( GILD )
lenacapavir, a twice-yearly injection, for preventing HIV
infection in adults and adolescents.
Gilead said the drug will be sold under the brand name
Yeztugo.